Emergent BioSolutions Inc. (NYSE:EBS) Shares Bought by Connor Clark & Lunn Investment Management Ltd.

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 902,332 shares of the biopharmaceutical company’s stock after buying an additional 69,157 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 1.67% of Emergent BioSolutions worth $8,626,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Prescott Group Capital Management L.L.C. boosted its holdings in Emergent BioSolutions by 250.0% in the 4th quarter. Prescott Group Capital Management L.L.C. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $2,008,000 after purchasing an additional 150,000 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Emergent BioSolutions in the 4th quarter valued at $98,000. SBI Securities Co. Ltd. purchased a new position in shares of Emergent BioSolutions during the 4th quarter worth $63,000. Wolverine Asset Management LLC acquired a new stake in shares of Emergent BioSolutions during the 4th quarter worth about $1,303,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in Emergent BioSolutions in the 4th quarter valued at about $201,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Emergent BioSolutions Trading Up 4.1 %

NYSE EBS opened at $5.74 on Friday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a market cap of $311.62 million, a price-to-earnings ratio of -1.40 and a beta of 1.80. The firm has a 50 day simple moving average of $8.92 and a 200-day simple moving average of $8.81. Emergent BioSolutions Inc. has a one year low of $1.82 and a one year high of $15.10.

Emergent BioSolutions (NYSE:EBS) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. The company had revenue of $194.70 million during the quarter, compared to analysts’ expectations of $254.67 million. During the same quarter last year, the company posted ($0.77) EPS. Equities research analysts anticipate that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

EBS has been the subject of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a research note on Tuesday, March 4th. StockNews.com cut shares of Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Insider Buying and Selling

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at $589,413. The trade was a 25.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.20% of the stock is currently owned by insiders.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.